NorthWest Biotherapeutics Inc (NWBO)

[Pyrrhonian]

Well I would certainly like more information on that too. I cannot just accept Bosch's word, an NWBO insider, that the two "cohorts," if you can call them that, were on equal footing. Especially considering they changed the inclusion criteria part way through the trial. Evidently a number of patients with < 6 months life expectancy and no monitoring of absolute lymph count (could be 50 mm3 and they could still get into the trial initially) were given DCs matured with Method A, being of course the first of two methods tested. We simply need more granularity: how many Method A patients were enrolled under the weaker criteria and how many Method B patients were, and how many Method A & B patients were enrolled under the stronger criteria (>6 months life expect and min 500 mm3 total lymph count)? Then let's talk about them being equal groups.